Mercados españoles abiertos en 8 hrs 41 min

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
0,9706+0,0170 (+1,78%)
Al cierre: 04:00PM EDT
0,9770 +0,01 (+0,66%)
Después del cierre: 06:07PM EDT

bluebird bio, Inc.

455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo323

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Andrew ObenshainPresident, CEO & Director1,04MN/A1974
Mr. Thomas J. KlimaChief Commercial Officer & COO654,97kN/A1972
Mr. Richard A. Colvin M.D., Ph.D.Chief Medical Officer696,24kN/A1966
Mr. Christopher Krawtschuk CPACFO, Principal Accounting Officer & TreasurerN/AN/A1974
Mr. Joseph D. Vittiglio Esq., J.D.Chief Legal & Business Officer and SecretaryN/AN/A1972
Jess RowlandsHead of Corporate CommunicationsN/AN/AN/A
Ms. Andrea WaltonChief People OfficerN/AN/AN/A
Mr. Kasra KasraianSenior Vice President of Technical Development & OperationsN/AN/AN/A
Mr. Scott ShoemakerSenior Vice President of QualityN/AN/AN/A
Ms. Sarah AlspachSenior Vice President of External AffairsN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de bluebird bio, Inc., a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 8; Tablero: 3; Derechos de los accionistas: 5; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.